CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...